tominersen   Click here for help

GtoPdb Ligand ID: 14718

Synonyms: HTT AO | IONIS-HTTRx | ISIS 443139 | ISIS-443139 | ISIS-HTT Rx | RG-6042 | RG6042 | RO7234292
Compound class: Nucleic acid
Comment: Tominersen (ISIS-443139, RG-6042) is an allele-nonselective antisense oligonucleotide (ASO) gapmer [1] that was intended to reduce production of huntingtin (HTT) protein (mutant and wild-type).

Chemically tominersen is a 20-mer 2'-O-methoxyethyl (2'-MOE) oligonucleotide with a phosphorothioate (PS) backbone.
Full sequence is:
all-P-ambo-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl- (3'→5')-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-O-(2-methoxyethyl)adenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)adenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidine
No information available.
Summary of Clinical Use Click here for help
Safety of tominersen (ISIS-443139, RG-6042) was demonstrated in clinical trial NCT02519036 [3]. It reached phase 3 investigations as a treatment for Huntington's disease [2], but development was discontinued in mid-2026 due to lack of efficacy to either improve clinical symptoms or slow disease progression.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02519036 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease Phase 1/Phase 2 Interventional Ionis Pharmaceuticals, Inc.
NCT03342053 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) Phase 2 Interventional Hoffmann-La Roche
NCT03842969 An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies Phase 3 Interventional Hoffmann-La Roche
NCT03761849 A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease Phase 3 Interventional Hoffmann-La Roche